GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cybin Inc (AMEX:CYBN) » Definitions » Debt-to-Asset

Cybin (CYBN) Debt-to-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Cybin Debt-to-Asset?

Cybin's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.24 Mil. Cybin's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.03 Mil. Cybin's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $96.69 Mil. Cybin's debt to asset for the quarter that ended in Dec. 2023 was 0.00.

Cybin Debt-to-Asset Historical Data

The historical data trend for Cybin's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cybin Debt-to-Asset Chart

Cybin Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Debt-to-Asset
- - - -

Cybin Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cybin's Debt-to-Asset

For the Biotechnology subindustry, Cybin's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cybin's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cybin's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Cybin's Debt-to-Asset falls into.


Cybin Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Cybin's Debt-to-Asset for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 0) / 39.39
=0.00

Cybin's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.242 + 0.031) / 96.694
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cybin  (AMEX:CYBN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Cybin Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Cybin's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cybin (CYBN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cybin Inc (AMEX:CYBN) » Definitions » Debt-to-Asset
Comparable Companies
TSX:FRX TSX:SVA TSX:ONC NEOE:MMED TSX:EPRX XCNQ:DTC TSXV:NGEN TSX:BCT XCNQ:MSET TSXV:ARCH OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
R7E1:Germany R7E1:Germany CYBN:Canada
Address
100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Website
https://www.cybin.com
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various psychiatric and neurological conditions.